DrugPatentWatch Database Preview
CIMZIA Drug Profile
» See Plans and Pricing
Summary for Tradename: CIMZIA
Recent Clinical Trials for CIMZIA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| UCB Biopharma S.P.R.L. | Phase 1 |
| University of California, San Francisco | Phase 1 |
| UCB Biopharma S.P.R.L. | Phase 3 |
Recent Litigation for CIMZIA
Identify key patents and potential future biosimilar entrants
PTAB Litigation
| Petitioner | Date |
|---|---|
| 2017-12-20 |
Pharmacology for CIMZIA
| Mechanism of Action | Tumor Necrosis Factor Receptor Blocking Activity |
Patent Text Search: US Patents for CIMZIA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | CIMZIA | certolizumab pegol | INJECTABLE; INJECTION | 125160 | 001 | 2008-04-22 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Ucb Inc | CIMZIA | certolizumab pegol | INJECTABLE; INJECTION | 125160 | 001 | 2008-04-22 | Start Trial | Knopp Biosciences LLC (Pittsburgh, PA) | 2033-08-13 | RX | search | |
| Ucb Inc | CIMZIA | certolizumab pegol | INJECTABLE; INJECTION | 125160 | 001 | 2008-04-22 | Start Trial | Agency for Science, Technology and Research (Singapore, SG) | 2033-02-13 | RX | search | |
| Ucb Inc | CIMZIA | certolizumab pegol | INJECTABLE; INJECTION | 125160 | 001 | 2008-04-22 | Start Trial | Nestec S.A. (Vevey, CH) | 2031-05-10 | RX | search | |
| Ucb Inc | CIMZIA | certolizumab pegol | INJECTABLE; INJECTION | 125160 | 001 | 2008-04-22 | Start Trial | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
| Ucb Inc | CIMZIA | certolizumab pegol | INJECTABLE; INJECTION | 125160 | 001 | 2008-04-22 | Start Trial | ORBSEN THERAPEUTICS LIMITED (Galway, IE) | 2035-03-20 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for CIMZIA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2014508801 | Start Trial |
| Singapore | 10201802127U | Start Trial |
| World Intellectual Property Organization (WIPO) | 2015006708 | Start Trial |
| Australia | 2006304418 | Start Trial |
| Cyprus | 1117165 | Start Trial |
| Croatia | P20170038 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CIMZIA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2020C/505 | Belgium | Start Trial | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| PA2020505 | Lithuania | Start Trial | PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| 122020000011 | Germany | Start Trial | PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| 301035 | Netherlands | Start Trial | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218 |
| LUC00149 | Luxembourg | Start Trial | PRODUCT NAME: UPADACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| 132020000000022 | Italy | Start Trial | PRODUCT NAME: UPADACITINIB IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(RINVOQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1404, 20191218 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
